1 / 25

New JCAHO/Inspection Standards – P&T Implications & Critical Elements of Design

New JCAHO/Inspection Standards – P&T Implications & Critical Elements of Design. Phil L. Samples, Col(s), USAF, BSC BSPhr, MS, PharmD., BCNSP Associate Director, Biomedical Sciences Corps Associate Corps Chief for Pharmacy, BSC. Overview. Membership Issues Requirements in policy

amber-drake
Download Presentation

New JCAHO/Inspection Standards – P&T Implications & Critical Elements of Design

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. New JCAHO/Inspection Standards – P&T Implications & Critical Elements of Design Phil L. Samples, Col(s), USAF, BSC BSPhr, MS, PharmD., BCNSP Associate Director, Biomedical Sciences Corps Associate Corps Chief for Pharmacy, BSC

  2. Overview • Membership Issues • Requirements in policy • Specific JCAHO issues • Implications of DoDI/AFAA • Strategies for Success

  3. Pharmacy & Therapeutics Directives • AF – controlled by AFI 44-102 • Medical staff function • Must meet minimum 4 times per year • Membership is prescribed • JCAHO – does not prescribe the make up but will survey to your policy

  4. Functions • Mandatory (AF) Functions • Reviews policies, acquisition and use of medications within the facility • Reviews medication errors (from ALL sources) • Reviews Adverse Drug Reactions (ADRs) • Evaluates clinical data on new medications and preparations for use at the MTF

  5. Membership • Members – WHY? • 2 physicians • 1 dentist • 1 pharmacist • 1 nurse • The Chief of Medical Logistics • Remember, JCAHO – does not prescribe the make up but will survey to your policy • Possible additions – Resource manager, other interested parties (be careful, the committee can become too cumbersome and difficult to achieve quorum)

  6. JCAHO Implications and Issues

  7. Periodic Performance Review • Review all standards and identify areas for improvement to include National Patient Safety Goals (NPSG) • Develop plan of action for deficiencies • Deficiency identified in an Element of Performance (EP) designated with an “M” must identify measure of success • Phone conference with JCAHO to approve plan • Measure of Success will be reviewed during survey

  8. Plan of Action • Describe planned action for each Element of Performance (EP) marked as partial or insufficient compliance • For each EP where a measure of success is required describe: • What will bring standard into compliance • How action will result in improvement • How will you know – measurable objective criteria, performance improvement (PI) data, inspection, interviews

  9. Definition of Medication • DRASTIC CHANGE! • Medications Include – standards apply to all of these

  10. Definition of Medication • What is NOT included: • Enteral Nutrition Products • Oxygen • Other medical gases

  11. Safe Medication Management Safe Medication Management Patient Specific Information –MM.1.10 Six Critical Processes Selection & Procurement Storage Ordering & Transcribing MM.2.10 MM.2.20, 2.30, 2.40 MM.3.10, 3.20 Preparing & Dispensing Administration Monitoring MM.4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8 MM.5.10, 5.20 MM.6.10, 6.20 Special Case High Risk Medications MM.7.10, 7.20, 7.30, 7.40 Evaluation – MM.8.10

  12. Selection & Procurement MM.2.10 • Criteria for addition and deletion to formulary • Must include propensity for medication errors, abuse potential and sentinel events • MUST be able to monitor med PRIOR to addition (e.g. new lab or radiographic procedure) • ANNUAL review of meds based on emerging data • Black box warning • Process to approve & procure meds not on formulary • Orders for non-formulary meds must be approved by an abbreviated process • Process for handling medication shortages • Communication with staff, developed substitutes, education about protocols, obtaining during disaster

  13. Selection & Procurement MM.2.10 • Compliance tips • Document process in P&T Minutes • Document evidence of sound alike, look alike potential • Excellent sources – USP and ISMP • Document ability to monitor • Antibiotic sensitivity • Anticoagulant monitoring • Appropriate equipment in treatment area • Develop abbreviated procedure for non-formulary approval

  14. Proper and Safe Storage MM.2.20 • P & T Considerations should document issues concerning consequences of storage • Only approved meds are stocked and/or stored • Segregation of look-alike, sound alike meds • Medication concentrations are standardized • NO, repeat NO, concentrated electrolytes in patient care areas (example of exception – perfusionist in cardiac surgery) • Meds in most ready-to-use form

  15. NPSG Specific Requirements of P&T • Unapproved abbreviation list must include • U (for units) • IU (for international units) • Q.D. (for once daily) • Q.O.D. (for every other day) • Trailing zero (e.g. 3.0mg) • Lack of leading zero (e.g., .3mg) • MS or MSO4 (for morphine sulfate or magnesium sulfate) • MgSO4 (for magnesium sulfate)

  16. NPSG Specific Requirements of P&T • Unapproved abbreviations (con’t) • Must include 3 new items not on mandatory list by 1 Apr 04 • Will include electronic and print media by 2005

  17. Monitoring MM.6.10, 6.20 • Develop and document strategy to monitor the first few doses of a medication new to the patient • Aggregate and analyze data • ADR • MUE/DUE/AUE

  18. High Risk Medications MM.7 • P&T must identify high-risk medications • Document safety steps taken in each area of medication use system • Tips • Approve and publish list of high-risk medications • Develop grid (see next slide)

  19. High Risk Medications MM.7

  20. Evaluation MM.8.10 • Evaluate literature and document actions • ISMP Patient Safety Alerts or USP – good sources of data • Review internal data for trends or other issues regarding medication safety • Good sources - ADR and MUEs

  21. Successful Hints for the P&T • Sub-committees (depending on facility size) • New drug requests • MUEs • Write liberal policies wherever possible • Must meet at least 4 times per year • Ensure medical staff buy in • Select thought leaders to serve • Properly vet your minutes through the commander, either directly or through Exec Committee (CC is ultimate authority for obligation of funds)

  22. Successful Hints for the P&T • Detailed Minutes • (OPEN: Jul 03, ECD: 12/03, OPR: CMO, OCR: SGA) • Enough detail to allow a new person to understand • Refer to higher committee when needed • Mark compliance issues in minutes • Note in margin • Group together • Documentation of Physician involvement

  23. Keys to Successful Survey • Clean and organized • Secure all medications – pharmacy MUST control all medications in all areas • Concentrate on Problematic Areas (crash carts, anesthesia, etc.) • Emphasize Safe Use of Medications – NPSG! • Develop Good P&T Minutes • Demonstrate Competence • Customize Policies and Procedures • Educate and rehearse • Take credit for improvements and positive outcomes

More Related